Viveve Medical, Inc. Quarterly report pursuant to Section 13 or 15(d)

[1]	Each share of Series A convertible preferred stock was convertible at any time at the holder's option into one share of common stock. As of June 30, 2020, all Series A convertible preferred stock had been converted into common stock and there were no remaining shares outstanding. In December 2020, the Company filed a Certificate of Elimination with the Delaware Secretary of State with respect to the authorized shares of Series A convertible preferred stock.
[2]	As of June 30, 2021 and 2020, a total of 38,090 and 33,685 shares of Series B convertible preferred stock were outstanding and convertible into 2,489,542 and 2,201,634 shares of common stock, respectively. Each share of Series B convertible preferred stock is convertible at the holder's option into shares of common stock at a conversion ratio of 1-for-65.36 per share determined by dividing the Series B liquidation amount of $1,000 per share by the Series B conversion price of $15.30 per share. However, under the terms of the Series B Preferred Stock and Warrant Purchase Agreement, as amended, CRG will not convert the Series B preferred stock or exercise the CRG warrants until the Company's stockholders act to authorize additional number of shares of common stock sufficient to cover the conversion shares.
[3]	Each share of Series C preferred stock is convertible at any time at the holder's option into one share of common stock. As of June 30, 2021, all Series C convertible preferred stock had been converted into common stock and there are no remaining shares of Series C convertible preferred stock outstanding.